China (Mainland)
Diamondsupplier 
factory supply GMP,DMF,CEP Entecavir CAS NO.142217-69-4
- Min.Order: 1 Kilogram
- Payment Terms: L/C,T/T,Other
- Product Details
Keywords
- Entecavir
- Anti hepatitis B virus
- 142217-69-4
Quick Details
- ProName: factory supply GMP,DMF,CEP Entecavir
- CasNo: 142217-69-4
- Molecular Formula: C15H18
- Appearance: White crystallization
- Application: Anti hepatitis B virus
- DeliveryTime: in two weeks
- PackAge: 1kg/tin
- Port: SHANGHAI BEIJING
- ProductionCapacity: 1 Metric Ton/Day
- Purity: USP/EP/BP
- Transportation: AIR SEA TRAIN
- LimitNum: 1 Kilogram
Superiority
We are very compeitive on Entecavir.Our mfr is GMP certified for this item with CEP document.
| Product Name: | Entecavir |
| CAS: | 142217-69-4 |
| MF: | C12H15N5O3 |
| MW: | 277.28 |
| EINECS: | 604-279-5 |
| Product Categories: | The latest anti hepatitis b anti-aids drugs;Anti-virals;Nucleotides and Nucleosides;Bases & Related Reagents;API;Heterocycles;Antiviral Agents;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals;Inhibitors |
| Mol File: | 142217-69-4.mol |
Details
| Hepatitis B treatment first-line drug | Entecavir is a new generation of guanine nucleoside analogues oral medicine for treatment of hepatitis B virus infection in, mainly for the treatment of adult patients with viral replication activity and serum transaminase continued to increase, or liver tissue for pathological activity of chronic hepatitis B, is currently down virus the fastest and the most powerful, the mutation rate lowest nucleoside analogues. Data show that different in patients with chronic hepatitis B, including nucleoside naive and nucleoside treated and liver cirrhosis patients, using well entecavir tablets in the treatment can control the disease rapidly and easily reach the treatment of reality end, namely the hepatitis B virus unmeasured; through adherence to treatment, a considerable portion of patients can be arrived at the end of treatment satisfaction, namely e antigen serology conversion, some patients can even reach the ideal for the treatment of end, namely surface antigen negative. |
